Stock screener

RNA

Conviction 20HealthcareScan · Fri, Oct 2, 2026

Atrium Therapeutics, Inc. (RNA) closed at $7.84 (-3.69%) on Oct 2, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 23, RS Rating 33, -52.6% from its 52-week high, -45.6% year to date. Sector: Healthcare · Biotechnology.

RNA$7.84-3.69%
ResistanceSupportVol 14
63 bars
Vol MA14 411.57K
Jul 7Jul 23Aug 11Aug 27Sep 16Oct 2
WSB mentions · 24h changelatest +200.00%· 3 mentions
Jul 7Jul 23Aug 11Aug 27Sep 16Oct 2
Atrium Therapeutics, Inc.Biotechnologywww.aviditybiosciences.com ↗
Price7.84
Change-3.69%
Gap+0.00%
Rel volume6.20×
Avg volume574.68K
Avg $ vol5.34M
SMA 209.47
SMA 5011.40
SMA 20013.07
Price vs 50-31.21%
Price vs 200-40.03%
MA stackbearish
50/200 cross—
Supertrenddown · 9.55
RSI (14)23
MACD hist-0.07
MACD cross—
Stoch %K / %D6 / 7
ADX (14)45
+DI / −DI11 / 40
RSI divergence—
MACD divergence—
ATR %7.01%
ADR %6.75%
52w high16.54
52w low7.84
From 52w high-52.60%
Above 52w low+0.00%
New 52w highNo
SqueezeOff
Bollinger width61.35%
%B0.22
Donchian pos2.01%
Donchian high14.65
Donchian low7.70
AVWAP (52w high)12.52
vs AVWAP high-37.39%
AVWAP (52w low)7.93
vs AVWAP low-1.11%
OBV trendDown
Chaikin MF (20)-0.38
Today vs 20d6.20×
Avg vol (14d)570.56K
Avg vol (20d)574.68K
Avg $ vol (20d)5.34M
Market cap134.11M
RS Rating33 / 99
RS 3m (vs SPY)-42.18%
RS 6m (vs SPY)-59.02%
RS line new highNo
Trend template0/8
Technical rank8.8
1 week-5.43%
1 month-44.24%
3 months-39.74%
6 months-41.67%
1 year-10.03%
YTD-45.63%
P/E—
P/B0.63
P/S—
P/FCF—
EPS—
Div yield—
ROE—
ROA—
Debt/Eq—
Current8.73
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target—
Target upside—
Analyst rating—
Institutional95.39%
Ent. value61.77M
Revenue3M
Net income-20.19M
Gross profit—
Free cash flow—
IndustryBiotechnology
ExchangeNasdaq
Shares out17.11M
Employees391
ListedFri, Feb 27, 2026
Free float16.24M
Float %94.9%
Short interest3.35M
Days to cover19.8d
Short volume40.1%
Squeeze score80 / 100
Next earnings—
EPS forecast—
Last EPS vs est−$1.18
Last surprise—
Setup gradeD
Conviction20 / 100
Pattern quality—
Tech rank8.8 / 100
Group rank14 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance14.39
Support8.36
Days since event—
Candle confirm—

Financials as of Tue, Jun 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in RNA

All disclosures →
No recent disclosed trades by Congress in RNA. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in RNA

InsiderSideShares
Kenney Stephanie
See Remarks · Common Stock · 2026-04-20
Grant30K
Hughes Steven George
Chief Medical Officer · Stock Option (Right to Buy) · 2026-04-20
Grant60K
Kenney Stephanie
See Remarks · Stock Option (Right to Buy) · 2026-04-20
Grant60K
Hoyos Rocio Martin
Chief Strategy Officer · Common Stock · 2026-04-20
Grant30K
Winslow Brendan R.
Chief Financial Officer · Common Stock · 2026-04-20
Grant30K
Gallagher Kathleen P.
See Remarks · Stock Option (Right to Buy) · 2026-04-20
Grant205K
Hughes Steven George
Chief Medical Officer · Common Stock · 2026-04-20
Grant30K
Winslow Brendan R.
Chief Financial Officer · Stock Option (Right to Buy) · 2026-04-20
Grant60K
Gallagher Kathleen P.
See Remarks · Common Stock · 2026-04-20
Grant102.5K
Hoyos Rocio Martin
Chief Strategy Officer · Stock Option (Right to Buy) · 2026-04-20
Grant60K

SEC filings

EDGAR filings in RNA · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.